摘要
微小RNA(micro RNAs)是一类重要的高度保守的内源性、非编码RNA,在转录后水平调节着基因的表达。micro RNAs的异常表达涉及肿瘤发生发展的各个过程,因具备成为肿瘤的生物学标志和治疗靶点的潜能而被广泛研究。在众多肿瘤细胞中,micro RNA-125b(mi R-125b)的异常表达被广泛证实,而研究相对深入的即为浸润性乳腺癌。作为在浸润性乳腺癌细胞系和在体肿瘤细胞中显著改变的micro RNA,学界对mi R-125b所担任的角色是抑癌基因还是促癌基因存在争论。在此笔者将概述现有关于mi R-125b在浸润性乳腺癌的发生、发展、诊断、预后及药物抗性中发挥的各类生物学作用。借此,更好的理解mi R-125b在浸润性乳腺癌基因网络中的角色,有助于探究mi R-125b在未来成为浸润性乳腺癌诊断标志或者治疗靶点的生物学前景,甚至探索其在肿瘤中的全部潜能。
MicroRNAs （miRNAs） are a critical class of evolutionarily conserved non-coding endogenous RNA molecules that regulate gene expression post-transcriptionally. Thousands of miRNAs are reported to play irreplaceable roles in normal cell homeostasis, cell metastasis and disease pathogensls and progression, and they have lately been widely studied due to their potential function as diagnostic biomarks and targets for cancer therapy. The link between miRNA-125b deregulation and many types of cancer has been validated, including invasive breast cancer. As a significant deregulated signature, miR-125b is reported to have paradoxical functions as either oncogene-like or tumor suppressor-like in invasive breast cancer or cell lines. In this review, we summarized the implication of miR-125b in various celluar biological activities including tumorigenesis, progression, diagnose, prognosis, chemoresistanc. Therefore, better understanding of miR-125b＇s role in gene network of invasive breast cancer may help exploit the potential of miR-125b in regards to cancer diagnosis, treatment, and chemoresistanc, even the full potential of miRNAs in all types of cancer.
出处
《中国现代医学杂志》
CAS
北大核心
2015年第13期48-53,共6页
China Journal of Modern Medicine
基金
中南大学研究生自主创新基金(No:2014zzts365)
